Loxo Oncology (LOXO) Reports In-Line Q3 Loss

Loxo Oncology (NASDAQ: LOXO) reported Q3 EPS of ($0.53), in-line with the analyst estimate of ($0.53).

For earnings history and earnings-related data on Loxo Oncology (LOXO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15